Evidence map›Paper›PMID 41285479›Full record

ReviewEndocrine journal2026

Congenital adrenal hypoplasia with neurodevelopmental delay due to contiguous Xp21 deletion: a case series with review of literature.

Maki Gau, Ryosei Iemura, Ryuta Orimoto, Eriko Adachi, Yoko Saito, Haruki Yamano, Hisae Nakatani, Shizuka Kirino, Haruka Kuno, Kengo Moriyama and 8 more

Abstract readCase ReportsReview
In one paragraph

Review in Endocrine journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Maki GauDepartment of Life Science and Bioethics, Institute of Science Tokyo, Tokyo 113-8510, Japan.ORCID http://orcid.org/0000-0002-0318-5472
Ryosei IemuraDepartment of Pediatrics and Developmental Biology, Institute of Science Tokyo, Tokyo 113-8510, Japan.
Ryuta OrimotoDepartment of Pediatrics and Developmental Biology, Institute of Science Tokyo, Tokyo 113-8510, Japan.
Eriko AdachiDepartment of Pediatrics and Developmental Biology, Institute of Science Tokyo, Tokyo 113-8510, Japan.ORCID http://orcid.org/0009-0001-5260-7571
Yoko SaitoDepartment of Pediatrics and Developmental Biology, Institute of Science Tokyo, Tokyo 113-8510, Japan.ORCID http://orcid.org/0009-0004-2975-8656
Haruki YamanoDepartment of Pediatrics and Developmental Biology, Institute of Science Tokyo, Tokyo 113-8510, Japan.ORCID http://orcid.org/0009-0000-5434-3664
Hisae NakataniDepartment of Pediatrics and Developmental Biology, Institute of Science Tokyo, Tokyo 113-8510, Japan.ORCID http://orcid.org/0000-0002-8502-222X
Shizuka KirinoDepartment of Pediatrics and Developmental Biology, Institute of Science Tokyo, Tokyo 113-8510, Japan.ORCID http://orcid.org/0009-0001-0991-4330
Haruka KunoDepartment of Pediatrics, Japanese Red Cross Tokyo Katsushika Perinatal Center, Tokyo 125-0051, Japan.
Kengo MoriyamaDepartment of Pediatrics and Developmental Biology, Institute of Science Tokyo, Tokyo 113-8510, Japan.
Yohei YamaguchiDepartment of Pediatrics and Developmental Biology, Institute of Science Tokyo, Tokyo 113-8510, Japan.ORCID http://orcid.org/0000-0002-4615-043X
Yoshiki OitaniDepartment of Pediatrics, Tokyo Women's Medical University Adachi Medical Center, Tokyo 123-8558, Japan.ORCID http://orcid.org/0000-0002-2769-1484
Manabu SugieDepartment of Pediatrics and Developmental Biology, Institute of Science Tokyo, Tokyo 113-8510, Japan.ORCID http://orcid.org/0000-0002-9563-2312
Tomoko MizunoDepartment of Pediatrics and Developmental Biology, Institute of Science Tokyo, Tokyo 113-8510, Japan.
Taku IshiiDepartment of Pediatrics and Developmental Biology, Institute of Science Tokyo, Tokyo 113-8510, Japan.ORCID http://orcid.org/0000-0003-3628-5039
Masayuki YoshidaDepartment of Life Science and Bioethics, Institute of Science Tokyo, Tokyo 113-8510, Japan.
Kenichi KashimadaDepartment of Pediatrics and Developmental Biology, Institute of Science Tokyo, Tokyo 113-8510, Japan.ORCID http://orcid.org/0000-0003-2505-5932
Kei TakasawaDepartment of Pediatrics and Developmental Biology, Institute of Science Tokyo, Tokyo 113-8510, Japan.ORCID http://orcid.org/0000-0001-6947-4034

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

X-linked adrenal hypoplasia congenita (AHC) is a rare, life-threatening disorder caused by pathogenic variants in NR0B1 (DAX1), leading to adrenal insufficiency and hypogonadotropic hypogonadism. AHC is often associated with Xp21 contiguous gene deletion syndrome, which involves the deletion of multiple genes, including NR0B1, GK, DMD, and IL1RAPL1, resulting in a spectrum of phenotypic manifestations, such as glycerol kinase deficiency (GKD), Duchenne muscular dystrophy (DMD), and neurodevelopmental disorders. We report two cases of AHC with neurodevelopmental delays due to contiguous Xp21 deletions involving NR0B1 and IL1RAPL1, each diagnosed through distinct clinical pathways. Case 1 involved a neonate with adrenal insufficiency, persistent hyperCKemia, and excessive urinary glycerol excretion, leading to a diagnosis of Xp21 deletion syndrome with DMD and GKD. The patient's sister, an asymptomatic carrier, exhibited elevated CK levels and mild developmental delays. Array comparative genomic hybridization identified a novel complex structural variation, including duplication-deletion-duplication rearrangement, which may have modified clinical manifestations. Case 2 involved a 10-year-old boy with AHC and developmental delay that was initially considered a consequence of adrenal crises. Genetic analysis confirmed an Xp21 deletion, including IL1RAPL1, implicating it in his intellectual disability. A literature review reveals that Xp21 deletions involving IL1RAPL1 are strongly associated with neurodevelopmental delays, suggesting a distinct phenotype within Xp21 deletion syndromes. Early genetic diagnosis via chromosomal microarray analysis facilitates precise delineation of deletion regions, aiding in clinical management, genetic counseling, and early intervention strategies. Further studies are needed to elucidate genotype-phenotype correlations in Xp21 deletion syndromes and optimize individualized medical care.

Indexed as

Adrenal InsufficiencyChromosomes, Human, XDevelopmental DisabilitiesGenetic Diseases, X-LinkedNeurodevelopmental DisordersChildChromosome DeletionDAX-1 Orphan Nuclear ReceptorFemaleGene DeletionGlycerol KinaseHumansInfant, NewbornInterleukin-1 Receptor Accessory ProteinMaleDAX-1 Orphan Nuclear ReceptorGlycerol KinaseIL1RAPL1 protein, humanInterleukin-1 Receptor Accessory ProteinNR0B1 protein, humanX-linked adrenal hypoplasia congenitalXp21 deletion syndromes

Identifiers

PMID41285479
PMCPMC12996724

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.